Amphastar Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
AMPH$29.06-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
(in thousands)
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||||||
| · 2023 · 2022 · 2021 | ||||||||||
| Net income attributable to Amphastar Pharmaceuticals, Inc. | | $137,545 | | $91,386 | | $62,116 | | |||
| | | | | | | | | | | |
| Other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc., net of income taxes | | | | | | | | | | |
| Reclassification of adjustment for amounts included in net income | | | — | | | — | | | (362) | |
| Foreign currency translation adjustment | | 298 | | (2,335) | | (2,943) | | |||
| Change in pension obligations | | (152) | | | 476 | | | 261 | | |
| Total other comprehensive income (loss) attributable to Amphastar Pharmaceuticals, Inc. | | 146 | | (1,859) | | (3,044) | | |||
| | | | | | | | | | | |
| Total comprehensive income attributable to Amphastar Pharmaceuticals, Inc. | | $137,691 | | $89,527 | | $59,072 | | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.